Polar Capital’s Aimmune Therapeutics AIMT Stock Holding History

Polar Capital’s Portfolio AIMT Stock Details AIMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-10,152	Closed	-$170K	–	331
2020 Q2	$170K	Buy	+10,152	New	+$172K	﹤0.01%	278

Other funds holding AIMT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

AAM

Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return

Gabelli Funds Rye, New York $14.8B AUM 32.24% 1-Year Est. Return

WIC

Water Island Capital New York $896M AUM 107.59% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Polar Capital's AIMT Position: Q3 2020 in Review

Polar Capital sold out of Aimmune Therapeutics (AIMT) in Q3 2020, closing a stake of 10,152 shares — an estimated $170K sold.

Polar Capital first reported a position in AIMT in Q2 2020 and held it in 1 quarter. The position peaked at $170K in Q2 2020. 188 funds tracked by Wall St. Rank hold AIMT as of Q3 2020.

Polar Capital reported no remaining Aimmune Therapeutics position as of Q3 2020 after selling out during the quarter.
Polar Capital sold 10,152 Aimmune Therapeutics shares in Q3 2020, an estimated $170K.
Polar Capital first reported a position in Aimmune Therapeutics in Q2 2020 and held it in 1 quarter.
Polar Capital's Aimmune Therapeutics position peaked at $170K in Q2 2020.
188 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q3 2020.

Based on Polar Capital's 13F filing for Q3 2020, filed 16 Nov 2020.